Progress signaling pathway in the pathogenesis of lymphoma cells

Mantle cell lymphoma (mantle ceul_ymphoma, MCL) accounts for about 6% B-cell non-Hodgkin's lymphoma, tumor cells derived from lymph nodes or primary follicular mantle zone of naive B cells, pathological types can be divided into classic type, small cell type, the mother and pleomorphic cell type. They have different growth characteristics and gene expression profiles.

Phenotype characterized by the expression of CD5 and B cell-associated antigens CD20, CD22, CD79, and strong expression of IgM IgD, but the lack of CD23, CD10 and expression of Bcl-6. Most of MCL patients showed aggressive clinical course, but recent studies have found that a small number of patients with MCL is inert clinical course, longer median overall survival of these patients.

Reproducibility has been reported cytogenetic abnormalities including 9p21.3,11q22.23 and 22q11.22 deletions, and 10p11.23 and 13q31-3 amplification, and P16, mutated ATM, CHEK2 and P53 in MCL patients also plays an important role.

As a cell signaling pathway necessary for life activities regulatory mechanisms in the biological behavior of tumor cells plays an important role. Gene expression profiling studies have found that at different stages of normal B cell development, gene expression levels related signaling pathways is insignificant, they are in B cell proliferation, differentiation and apoptosis plays an important role.

In the MCL. These signaling pathways associated with abnormal expression of genes but, MCL and is closely related to the occurrence and development. Therefore, raising awareness of these signaling pathways, Human Osteopontin ELISA Kit http://www.cusabio.com/ELISA_Kit-105826/ will help us to have a deeper understanding of the pathogenesis of MCL.